Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this research study is to determine if frailty assessments can be used to predict how well patients aged 60 years and older will do after chemotherapy, CAR T-cell therapy, or allogeneic stem cell transplant.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 60 lat lub więcej
- •Nowe rozpoznanie ostrej białaczki lub MDS (zespół mielodysplastyczny) lub podejrzenie takiej choroby
- •Planowane przeszczepienie szpiku kostnego lub terapia komórkami CAR T
- •Zdolność do wyrażenia świadomej zgody na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 60 Years
- Last updated (source)
- August 12, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Abramson Cancer Center of the University of Pennsylvania
Philadelphia, United States
Trial contact
Shannon McCurdy, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/13/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.